血栓性基因变异与伊朗人口血栓症之间的关联:系统性审查和元分析
Seyed Mehrab Safdari1, Azadeh Rezazadeh2, Danial Habibi3
1Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences.
概括
这项元分析确定了关键的遗传变异,如V因子Leiden和与伊朗人血栓友相关的前血突变. 这些发现有助于精确诊断和个性化治疗血栓性疾病.
科学领域:
- 遗传学 遗传学 是一个
- 血液学 血液学 血液学
- 人口健康 人口健康
背景情况:
- 受 V 莱登因子 (FVL) 和前血 G20210A 等遗传变异影响的血栓友爱症带来了诊断挑战.
- 评估许多遗传因素可能会导致临床实践中的错误和过度治疗.
- 在伊朗人群中,血栓友基因变异的作用尚未得到充分研究.
研究的目的:
- 在伊朗人口中进行与血栓性疾病相关的基因变异的元分析.
- 确定伊朗人中复发性妊娠丧失 (RPL),静脉血栓塞栓症 (VTE) 和深静脉血栓症 (DVT) 的特定遗传风险因素.
主要方法:
- 在PubMed,Scopus和Web of Science的系统文献搜索,查找到2025年7月的病例控制研究.
- 包括评估伊朗RPL,VTE或DVT患者血栓友多态性的研究.
- 应用随机效应,固定效应和贝叶斯元分析来计算几率比率 (OR) 和95%置信区间 (CI).
主要成果:
- 在36项研究 (14,000多名参与者) 中发现了显著的关联.
- 对于RPL,FVL G1691A,MTHFR C677T和A1298C (异子和同子),Prothrombin G20210A (异子和同子),PAI-1,FV A4070G,FV 5279A/G,FXIII Val34Leu和ITGB3 1565T/C都与增加的风险有关.
- FVL G1691A异构体 (OR:5.25) 增加了静脉瘤风险,而MTHFR C677T异构体 (OR:1.404) 增加了DVT风险.
结论:
- 这一元分析强调了伊朗人口特有的血栓性疾病的显著遗传风险因素.
- 已识别的基因变异,包括V-Leiden因子和MTHFR多态性,对于理解这一人口中的血栓友至关重要.
- 这些发现支持开发精确的诊断策略和针对伊朗人血栓状况的个性化干预措施.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
262
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
262
Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Venous Thrombosis I: Introduction
245
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
245
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K


